Watson Pharmaceuticals has acquired Greek drug maker Specifar Pharmaceuticals for $562 million, the two companies said Wednesday.
Watson said that through the acquisition, it had gained a leading generic product development company that develops and out-licenses products throughout the world, while also enhancing its commercial presence in Europe.
In addition, Watson said, acquiring Specifar would give it a branded-generic presence in Greece’s pharmaceutical market. Specifar is among the top five companies in the Greek branded-generic market.
See all the latest news from Greece and the world at Greekreporter.com. Contact our newsroom to report an update or send your story, photos and videos. Follow GR on Google News and subscribe here to our daily email!
